GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyowa Kirin Co Ltd (FRA:KY4) » Definitions » LT-Debt-to-Total-Asset

Kyowa Kirin Co (FRA:KY4) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Kyowa Kirin Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Kyowa Kirin Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

Kyowa Kirin Co's long-term debt to total assets ratio stayed the same from Jun. 2023 (0.00) to Jun. 2024 (0.00).


Kyowa Kirin Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Kyowa Kirin Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyowa Kirin Co LT-Debt-to-Total-Asset Chart

Kyowa Kirin Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kyowa Kirin Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kyowa Kirin Co LT-Debt-to-Total-Asset Calculation

Kyowa Kirin Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/6534.095
=0.00

Kyowa Kirin Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=0/6296.962
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyowa Kirin Co  (FRA:KY4) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Kyowa Kirin Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Kyowa Kirin Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyowa Kirin Co Business Description

Traded in Other Exchanges
Address
1-9-2,Otemachi, Chiyoda-ku, Otemachi Financial City Grand Cube, Tokyo, JPN, 100-0004
Kyowa Kirin Co Ltd is a drug manufacturing company that focuses on biologic medicines. Its operations emphasize four categories: nephrology, oncology, immunology and allergy, and the central nervous system. The company has two reportable segments, Pharmaceuticals and Biochemicals. The pharmaceuticals business manufactures and sells ethical pharmaceuticals, diagnostic reagents, and other products. The biochemicals business manufactures and sells raw materials for pharmaceutical and industrial use, mainly amino acids, nucleic acids and related compounds, healthcare products, and others.

Kyowa Kirin Co Headlines

No Headlines